Skip Nav Destination
Issues
1 October 2011
-
Cover Image
Cover Image
The cover figure depicts a homology model indicating the binding mode of a small molecule inhibitor complex with Axl kinase. The surface represents the active site residues and the spheres depict the hydrophobic and gatekeeper site residue interactions. In addition to the overall conserved structure of the kinase domain, the ATP-binding pockets of Axl and Mer possess features that establish molecular interactions with ATP that are common to other protein kinases. For details, see article by Verma and colleagues on page 1763. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Therapeutic Discovery
Identification of a Natural Compound by Cell-Based Screening That Enhances Interferon Regulatory Factor-1 Activity and Causes Tumor Suppression
Jinbo Gao; Yujun Wang; Quanhua Xing; Jin Yan; Maheswari Senthil; Yasir Akmal; Claudia M. Kowolik; Julia Kang; David M. Lu; Ming Zhao; Zhixiu Lin; Christopher H.K. Cheng; M.L. Richard Yip; John H. Yim
Telomere Targeting with a New G4 Ligand Enhances Radiation-Induced Killing of Human Glioblastoma Cells
Patrick Merle; Bertrand Evrard; Anne Petitjean; Jean-Marie Lehn; Marie-Paule Teulade-Fichou; Emmanuel Chautard; Anne De Cian; Lionel Guittat; Phong Lan Thao Tran; Jean-Louis Mergny; Pierre Verrelle; Andreï Tchirkov
A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
Koppany Visnyei; Hideyuki Onodera; Robert Damoiseaux; Kuniyasu Saigusa; Syuzanna Petrosyan; David De Vries; Denise Ferrari; Jonathan Saxe; Eduard H. Panosyan; Michael Masterman-Smith; Jack Mottahedeh; Kenneth A. Bradley; Jing Huang; Chiara Sabatti; Ichiro Nakano; Harley I. Kornblum
An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Georg E. Winter; Uwe Rix; Andrej Lissat; Alexey Stukalov; Markus K. Müllner; Keiryn L. Bennett; Jacques Colinge; Sebastian M. Nijman; Stefan Kubicek; Heinrich Kovar; Udo Kontny; Giulio Superti-Furga
Preclinical Development
NF-κB Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for γ-Irradiation–Induced Apoptosis
Rebecca Berger; Claudia Jennewein; Viola Marschall; Sabine Karl; Silvia Cristofanon; Liane Wagner; Sri HariKrishna Vellanki; Stephanie Hehlgans; Franz Rödel; Klaus-Michael Debatin; Albert C. Ludolph; Simone Fulda
The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors
Giuseppe Floris; Maria Debiec-Rychter; Agnieszka Wozniak; Cristiana Stefan; Emmanuel Normant; Gavino Faa; Kathleen Machiels; Ulla Vanleeuw; Raf Sciot; Patrick Schöffski
2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression
Carmine Stolfi; Roberta Caruso; Eleonora Franzè; Angelamaria Rizzo; Angela Rotondi; Ivan Monteleone; Massimo Claudio Fantini; Francesco Pallone; Giovanni Monteleone
Molecular Medicine in Practice
Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
Seung Tae Kim; Do Hyoung Lim; Kee-Taek Jang; Taekyu Lim; Jeeyun Lee; Yoon-La Choi; Hye-Lim Jang; Jun Ho Yi; Kyung Kee Baek; Se Hoon Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Joon Oh Park
BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
Tamar Safra; Lucia Borgato; Maria Ornella Nicoletto; Linda Rolnitzky; Sharon Pelles-Avraham; Ravit Geva; Martin Edward Donach; John Curtin; Akiva Novetsky; Tal Grenader; Wei-Chu V. Lai; Alberto Gabizon; Leslie Boyd; Franco Muggia
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.